Article
Safety, tolerability, and pharmacokinetics of long-acting injectable cabotegravir in low-risk HIV-uninfected individuals: HPTN 077, a phase 2a randomized controlled trial
Registro en:
LANDOVITZ, R. J. et al. Safety, tolerability, and pharmacokinetics of long-acting injectable cabotegravir in low-risk HIV-uninfected individuals: HPTN 077, a phase 2a randomized controlled trial. PLoS medicine, v. 15, n. 11, p. e1002690, 2018.
1549-1277
10.1371/journal.pmed.1002690
Autor
Landovitz, Raphael J
Li, Sue
Grinsztejn, Beatriz
Dawood, Halima
Liu, Albert Y
Magnus, Manya
Hosseinipour, Mina C
Panchia, Ravindre
Cottle, Leslie
Chau, Gordon
Richardson, Paul
Marzinke, Mark A
Hendrix, Craig W
Eshleman, Susan H
Zhang, Yinfeng
Tolley, Elizabeth
Sugarman, Jeremy
Kofron, Ryan
Adeyeye, Adeola
Burns, David
Rinehart, Alex R
Margolis, David
Spreen, William R
Cohen, Myron S
McCauley, Marybeth
Eron, Joseph J
Resumen
Cabotegravir (CAB) is a novel strand-transfer integrase inhibitor being developed for HIV treatment and prevention. CAB is formulated both as an immediate-release oral tablet for daily administration and as a long-acting injectable suspension (long-acting CAB [CAB LA]) for intramuscular (IM) administration, which delivers prolonged plasma exposure to the drug after IM injection. HIV Prevention Trials Network study 077 (HPTN 077) evaluated the safety, tolerability, and pharmacokinetics of CAB LA in HIV-uninfected males and females at 8 sites in Brazil, Malawi, South Africa, and the United States. 2019-12-08